Bevacizumab Efficiently Inhibits VEGF-Associated Cellular Processes in Equine Umbilical Vein Endothelial Cells: An In Vitro Characterization

Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilica...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary sciences 2023-10, Vol.10 (11), p.632
Main Authors: Lessiak, Ulrike, Pratscher, Barbara, Tichy, Alexander, Nell, Barbara
Format: Article
Language:English
Subjects:
Angiogenesis
anti-VEGF
Bevacizumab
Biotechnology industry
Cancer
Cancer therapies
Capillaries
Cell adhesion & migration
Cell culture
Cell growth
Cell migration
Cell viability
Cytotoxicity
Endothelial cells
Endothelium
equine umbilical vein endothelial cells
Ethylenediaminetetraacetic acid
Experiments
Eye diseases
Horses
Manufacturers
Musculoskeletal diseases
Oncology, Experimental
Physiological aspects
Umbilical vein
Vascular endothelial growth factor
Vascularization
Veins & arteries
Wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-VEGF agents were found to have clinical implications for the successful treatment of vascular-driven diseases in humans. In this study, a detailed biological characterization of bevacizumab in a variety of in vitro assays was carried out to determine the effect of bevacizumab on equine umbilical vein endothelial cells (EqUVEC). EqUVECs were harvested from umbilical cords of clinically healthy horses and exposed to different concentrations (1, 2, 4, 6, 8 mg/mL) of bevacizumab (Avastin®). Assays concerning the drug’s safety (cell viability and proliferation assay) and efficacy (cell tube formation assay, cell migration assay, and Vascular endothelial growth factor (VEGF) expression) were carried out reflecting multiple cellular processes. Bevacizumab significantly decreased VEGF expression at all concentrations over a 72 h period. No cytotoxic effect of bevacizumab on EqUVECs was observed at concentrations of 4 mg/mL bevacizumab or lower. Incubated endothelial cells showed delayed tube formation and bevacizumab efficiently inhibited cell migration in a dose-dependent manner. Bevacizumab potently inhibits VEGF-induced cellular processes and could be a promising therapeutic approach in vascular-driven diseases in horses.
ISSN:2306-7381
2306-7381
DOI:10.3390/vetsci10110632